Roth Capital Affirms Stemline Therapeutics (STML) at 'Buy'; Strong Cash Position Noted Ahead of ASH

November 8, 2016 11:22 AM EST
Get Alerts STML Hot Sheet
Price: $12.50 -1.57%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade STML Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Roth Capital affirms Stemline Therapeutics (Nasdaq: STML) at Buy with a price target of $32 following Q3 results.

Analyst Joseph Pantginis commented today, We believe an important event that occurred during 3Q16 is the granting of Breakthrough Therapy Designation to SL-401 for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although there were no clinical updates during the third quarter, we await updates on a number of programs at ASH in December including: 1) updated results from ongoing Phase II Trial of SL-401 in advanced MPN, 2) updated results from ongoing Phase II trial of SL-401 as consolidation therapy for AML patients in remission with high relapse risk including minimal residual disease (MRD), 3) updated results from ongoing Phase II trial expansion stage of SL-401 in Patients with BPDCN, and 4) updates to several preclinical studies of SL-401 and SL-801. With Breakthrough in hand, the major visibility we await is the outcome of the upcoming Type B meeting with the FDA by year end, in order to help finalize the registration path in BPDCN patients. Going into the Type B meeting, the company believes it has a critical mass of patient numbers to discuss filing, but is fully prepared for multiple permutations in defining the path forward, including post-approval requirements.

For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Roth Capital

Add Your Comment